期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
肠道益生菌辅助治疗对新生儿黄疸临床疗效及预后结局的影响
1
作者 李艳节 《中国科技期刊数据库 医药》 2023年第6期97-100,共4页
讨论肠道益生菌辅助治疗在新生儿黄疸中的使用价值。方法 收取本院2020.04-2022.09的89例新生儿黄疸患儿,随机分甲组(常规治疗,44例)、乙组(甲组+肠道益生菌辅助治疗,45例),对比组间临床效果。结果 相较于甲组,乙组总有效率、疗后生活... 讨论肠道益生菌辅助治疗在新生儿黄疸中的使用价值。方法 收取本院2020.04-2022.09的89例新生儿黄疸患儿,随机分甲组(常规治疗,44例)、乙组(甲组+肠道益生菌辅助治疗,45例),对比组间临床效果。结果 相较于甲组,乙组总有效率、疗后生活质量得分更高,不良反应发生率于疗后血清/经皮测胆红素更低(P>0.05)。结论 肠道益生菌辅助治疗新生儿黄疸疗效确切,值得使用。 展开更多
关键词 新生儿黄疸 益生菌辅助治疗 不良反应发生率 生活质量 血清胆红素
下载PDF
益生菌辅助治疗儿童消化性溃疡40例分析 被引量:1
2
作者 王泽龙 《中国药物与临床》 CAS 2020年第18期3080-3081,共2页
随着儿童消化性溃疡发病率逐年升高,幽门螺杆菌(Hp)感染是主要发病原因之一,根除Hp感染是降低消化性溃疡病发病率关键。目前我国Hp耐药菌株不断出现,耐药率逐年升高,根除率明显下降[1]。近年来随着益生菌辅助治疗根除Hp感染受到关注,同... 随着儿童消化性溃疡发病率逐年升高,幽门螺杆菌(Hp)感染是主要发病原因之一,根除Hp感染是降低消化性溃疡病发病率关键。目前我国Hp耐药菌株不断出现,耐药率逐年升高,根除率明显下降[1]。近年来随着益生菌辅助治疗根除Hp感染受到关注,同时能降低Hp感染根除过程中抗生素不良反应。本研究对40例学龄期患儿用益生菌辅助一线三联治疗消化性溃疡临床资料进行回顾与分析。 展开更多
关键词 消化性溃疡病 主要发病原因 儿童消化性溃疡 益生菌辅助治疗 学龄期患儿 根除率 不良反应 耐药
下载PDF
益生菌辅助治疗乙肝后肝硬化失代偿期的临床效果 被引量:1
3
作者 卢晶莹 《智慧健康》 2017年第7期108-109,共2页
目的分析对乙肝后肝硬化失代偿期患者使用益生菌辅助治疗的临床疗效。方法收集我院3年内收治的58例乙肝后肝硬化失代偿期患者。将其分为对照组29例和观察组29例。均需使用传统方法治疗。观察组在此基础上实施益生菌辅助治疗。结果观察... 目的分析对乙肝后肝硬化失代偿期患者使用益生菌辅助治疗的临床疗效。方法收集我院3年内收治的58例乙肝后肝硬化失代偿期患者。将其分为对照组29例和观察组29例。均需使用传统方法治疗。观察组在此基础上实施益生菌辅助治疗。结果观察组治疗有效率即血氨、转氨酶、胆红素水平明显优于对照组,差异均显著(P<0.05)。两组并发症率差异和HBV-DNA转阴率差异不显著(P>0.05)。结论对乙肝后肝硬化失代偿期患者治疗时,在常规方法基础上应用益生菌辅助治疗,可在保证安全性的前提下更好地改善临床疗效。 展开更多
关键词 益生菌辅助治疗 乙肝后肝硬化 失代偿期 临床效果
下载PDF
Whether Probiotic Supplementation Benefits Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis 被引量:8
4
作者 Hudan Pan Runze Li +2 位作者 Ting Li Jun Wang Liang Liu 《Engineering》 2017年第1期115-121,共7页
Gut and oral microflora are important factors in the pathogenesis and development of rheumatoid arthritis (RA). Recent studies have shown that probiotic supplements have beneficial consequences on experimental arthr... Gut and oral microflora are important factors in the pathogenesis and development of rheumatoid arthritis (RA). Recent studies have shown that probiotic supplements have beneficial consequences on experimental arthritis in rats. However, results from randomized clinical trials on the effects of probi- otics have not been consistent. The aim of this study was to systematically review the existing evidence for the effects of probiotic intervention in RA. We included randomized controlled trials (RCTs) of RA patients receiving stable treatment with disease-modifying anti-rheumatic drugs (DMARDs) that: ①were combined with additional probiotic supplements or ② were combined with either no additional supplements or only a placebo treatment. Statistical analysis was performed using Review Manager 5.3.3. Six randomized clinical trials were eligible for inclusion in the meta-analysis, with 249 participants in total. The results showed that the probiotic intervention treatment has not yet achieved significant improvement in the American College of Rheumatology 20% improvement criteria (ACR20) score and the disease activity score in 28 joints (DAS28). The laboratory index C-reactive protein (CRP) (mg.L-1) was significantly reduced in the intervention group. The expression of inflammatory cytokines tumor necrosis factor (TNF)-a and interleukine (IL)-ll] was also significantly reduced, while IL-10 expression increased in the probiotic intervention groups. This article is the first systematic review and meta-analysis providing a comprehensive assessment of the benefits of treating RA with probiotics. We found that probiotic supplementation may show a limited improvement in RA therapy in existing reports because of a lack of sufficiently high-quality work on the part of clinicians. More multi-centered, large-sample RCTs are needed in order to evaluate the benefits of probiotics in RA treatment. 展开更多
关键词 Rheumatoid arthritis Intervention Probiotic supplementation Systematic review Meta-analysis
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部